You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

Article metrics

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to December 2023

AbstractFullPdf
Nov 202185028
Dec 202173013
Jan 202289013
Feb 202293020
Mar 202242015
Apr 20223208
May 20225109
Jun 20228809
Jul 2022119011
Aug 202288013
Sep 202288013
Oct 20224904
Nov 20225602
Dec 20225005
Jan 20235808
Feb 20233703
Mar 20236404
Apr 20234302
May 20233004
Jun 20232707
Jul 20234606
Aug 20238007
Sep 20233605
Oct 20234305
Nov 2023104010
Dec 20231001
Total15810225